Applications of Xinnaoxin capsule in preparation of medicines treating cerebral ischemia-reperfusion injury
A technology of cerebral ischemia reperfusion and capsules, which is applied in the field of medicine to achieve the effect of reducing behavioral scores and improving hemodynamic indicators
Inactive Publication Date: 2015-01-07
三普药业有限公司
View PDF2 Cites 1 Cited by
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
However, its role in the treatment of cerebral ischemia-reperfusion injury has not been reported
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View moreImage
Smart Image Click on the blue labels to locate them in the text.
Smart ImageViewing Examples
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0013] The Xinnaoxin capsule is prepared by mixing 3 parts by weight of rhodiola rosea, 5 parts of wolfberry and 3 parts of seabuckthorn.
Embodiment 2
[0015] The Xinnaoxin capsule is prepared by mixing 4 parts by weight of rhodiola rosea, 10 parts of wolfberry and 6 parts of seabuckthorn.
Embodiment 3
[0017] The Xinnaoxin capsule is prepared by mixing 5 parts by weight of rhodiola rosea, 12 parts of wolfberry and 8 parts of seabuckthorn.
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more PUM
Login to view more Abstract
Applications of a Xinnaoxin capsule in preparation of medicines treating cerebral ischemia-reperfusion injury are disclosed. The applications prove that: the capsule significantly reduces behavioral scores, a cerebral infarction rate, a NO content and NOS activity of rats, improves blood rheological dynamic indexes and relaxes NE-precontracted vessels in a concentration-dependent manner.
Description
technical field [0001] The invention belongs to the field of medicine, and in particular relates to the application of Xinnaoxin Capsules in the preparation of medicines for treating cerebral ischemia-reperfusion injury. Background technique [0002] At present, ischemic cerebrovascular disease seriously affects the quality of human life. Cerebral ischemia, also known as cerebral infarction, is a type of disease caused by ischemia and hypoxia caused by cerebral blood flow disorder, resulting in localized ischemic necrosis or encephalomalacia, and cerebral ischemia-reperfusion injury is the cause of various Important pathophysiological mechanisms of cerebrovascular disease. Cerebral ischemia-reperfusion injury refers to the further aggravation of brain tissue damage after the blood perfusion of ischemic brain tissue is restored, and its mechanism has not been fully elucidated. In recent years, with the progress of shock treatment in clinical medicine and the promotion and a...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more Application Information
Patent Timeline
Login to view more Patent Type & Authority Applications(China)
IPC IPC(8): A61K36/815A61K9/48A61P9/10
CPCA61K36/41A61K9/48A61K36/185A61K36/815A61K2300/00
Inventor 史公权邹存生马俊仓吴留强夏彬牛蓉贺生玲李成秀
Owner 三普药业有限公司
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Try Eureka
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap